免疫检查点抑制剂相关甲状腺功能障碍中甲状腺激素替代治疗、基线促甲状腺激素与生存的特征分析
该回顾性队列纳入2012年12月1日至2019年12月31日接受免疫检查点抑制剂(ICI)治疗的成人癌症患者811例,排除28例既往原发性甲状腺功能减退者后评估新发ICI相关甲状腺功能障碍(ICI-TD)。中位随访19.2个月,122例(15.0%)发生ICI-TD;ICI-TD组中位左甲状腺素剂量在明显甲状腺功能减退组最高,为1.41 mcg/kg/天;校正永生时间偏倚后ICI-TD的生存获益不明显。
要点
- 811例接受ICI治疗的成人癌症患者中,122例(15.0%)发生新发ICI-TD,中位随访19.2个月。
- ICI-TD组中位治疗前log2(促甲状腺激素或TSH)为1.2(对应TSH 2.3 mIU/L),无ICI-TD组为0.79(对应TSH 1.7 mIU/L),p=0.008,但曲线下面积<0.6,缺乏预测能力。
- 校正永生时间偏倚并调整其他影响患者结局的变量后,ICI-TD的生存获益不明显。
核心结论
- ICI-TD所致明显甲状腺功能减退所需的左甲状腺素剂量与无甲状腺性甲状腺功能减退相似。
- 基线TSH处于正常范围上限与ICI-TD风险增加相关,但临床实践中无绝对基线TSH值能准确预测ICI-TD。
- 校正永生时间偏倚后,ICI-TD与总生存(OS)之间的关联需进一步验证。
研究设计与样本
- 回顾性队列研究,纳入2012年12月1日至2019年12月31日接受ICI治疗的成人癌症患者,排除28例既往原发性甲状腺功能减退者后,811例评估新发ICI-TD。
- 采用Kaplan-Meier生存曲线和log-rank检验比较ICI-TD状态组间OS分布,随后用Cox回归模型处理永生时间偏倚(ITB)。
主要发现
- 811例纳入患者中位随访19.2个月,122例(15.0%)发生ICI-TD。
- 开始ICI治疗时中位年龄64.8岁,女性占队列42.8%。
- 发生与未发生ICI-TD的患者在年龄、性别、种族、恶性肿瘤类型或自身免疫个人史方面无显著差异。
- ICI-TD最常见于联合ICI治疗(32%),与CTLA-4 ICI及PD-1/PD-L1 ICI单药治疗相比,p=0.002。
- 左甲状腺素中位剂量在明显甲状腺功能减退组最高,为1.41 mcg/kg/天。
关键数值与推荐
- ICI-TD组中位治疗前log2(促甲状腺激素或TSH)为1.2(对应TSH 2.3 mIU/L),无ICI-TD组为0.79(对应TSH 1.7 mIU/L),p=0.008。
- 曲线下面积<0.6,缺乏预测能力。
- 明显甲状腺功能减退组左甲状腺素中位剂量最高,为1.41 mcg/kg/天。
临床怎么用
- ICI-TD所致明显甲状腺功能减退的左甲状腺素替代剂量可与无甲状腺性甲状腺功能减退相似。
- 基线TSH处于正常范围上限与ICI-TD风险增加相关,但无绝对基线TSH值能准确预测ICI-TD。
- ICI-TD与OS的关联需在考虑永生时间偏倚后进一步验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroid dysfunction (TD) occurs commonly from immune checkpoint inhibitors (ICI) cancer therapy, but questions remain regarding its predicting factors, appropriate dosing for thyroid hormone replacement, and the strength of association with overall survival (OS). We aim to address these three questions in our study. Methods: We performed a retrospective cohort study of adult patients with cancer who received ICIs from December 1, 2012, to December 31, 2019. After excluding 28 patients with preexisting primary hypothyroidism, 811 patients were evaluated for the development of new-onset ICI-TD. Kaplan-Meier survival and log-rank tests were used to compare OS distributions between ICI-TD status groups, following which Cox regression models addressed immortal time bias (ITB). Results: Of the 811 included patients with a median follow-up of 19.2 months, 122 (15.0%) patients developed ICI-TD. The median age at initiation of ICIs was 64.8 years; women comprised 42.8% of the cohort. There were no significant differences in age, sex, race, malignancy type, or personal history of autoimmunity in patients who developed ICI-TD versus those who did not. ICI-TD occurred most frequently after combination ICI therapy (32%) compared with CTLA-4 ICI and PD-1/PD-L1 ICI monotherapy (p = 0.002). The median levothyroxine dose was the highest, being 1.41 mcg/kg/day in the overt hypothyroidism group. Patients with ICI-TD had a higher median pre-treatment log2(thyrotropin or TSH) level (1.2, corresponding to TSH 2.3 mIU/L) versus those without (0.79, corresponding to TSH 1.7 mIU/L; p = 0.008); however, the area under the curve was <0.6, hence lacking predictive ability. The survival benefit of ICI-TD was not apparent after addressing ITB and adjusting for other variables affecting patient outcomes. Conclusions: The levothyroxine dose needed for overt hypothyroidism from ICI-TD is similar to athyreotic hypothyroidism. While baseline TSH in the upper normal range is associated with an increased risk of ICI-TD, there is no absolute baseline TSH value that accurately predicts ICI-TD in the clinical setting. The link between ICI-TD and OS needs further validation after accounting for ITB.
引用
- Abdallah D, Johnson J, Qiu F, et al. Characterizing Thyroid Hormone Replacement, Baseline Thyrotropin, and Survival in Immune Checkpoint Inhibitor-Associated Thyroid Dysfunction. Thyroid. 2025. PMID: 40559206. doi:10.1089/thy.2025.0076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。